Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2010-7-30
pubmed:abstractText
Novel therapeutics to overcome the toxic effects of organophosphorus (OP) chemical agents are needed due to the documented use of OPs in warfare (e.g. 1980-1988 Iran/Iraq war) and terrorism (e.g. 1995 Tokyo subway attacks). Standard OP exposure therapy in the United States consists of atropine sulfate (to block muscarinic receptors), the acetylcholinesterase (AChE) reactivator (oxime) pralidoxime chloride (2-PAM), and a benzodiazepine anticonvulsant to ameliorate seizures. A major disadvantage is that quaternary nitrogen charged oximes, including 2-PAM, do not cross the blood brain barrier (BBB) to treat brain AChE. Therefore, we have synthesized and evaluated pro-2-PAM (a lipid permeable 2-PAM derivative) that can enter the brain and reactivate CNS AChE, preventing seizures in guinea pigs after exposure to OPs. The protective effects of the pro-2-PAM after OP exposure were shown using (a) surgically implanted radiotelemetry probes for electroencephalogram (EEG), (b) neurohistopathology of brain, (c) cholinesterase activities in the PNS and CNS, and (d) survivability. The PNS oxime 2-PAM was ineffective at reducing seizures/status epilepticus (SE) in diisopropylfluorophosphate (DFP)-exposed animals. In contrast, pro-2-PAM significantly suppressed and then eliminated seizure activity. In OP-exposed guinea pigs, there was a significant reduction in neurological damage with pro-2-PAM but not 2-PAM. Distinct regional areas of the brains showed significantly higher AChE activity 1.5h after OP exposure in pro-2-PAM treated animals compared to the 2-PAM treated ones. However, blood and diaphragm showed similar AChE activities in animals treated with either oxime, as both 2-PAM and pro-2-PAM are PNS active oximes. In conclusion, pro-2-PAM can cross the BBB, is rapidly metabolized inside the brain to 2-PAM, and protects against OP-induced SE through restoration of brain AChE activity. Pro-2-PAM represents the first non-invasive means of administering a CNS therapeutic for the deleterious effects of OP poisoning by reactivating CNS AChE.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-10421556, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-11701190, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-1246030, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-13016586, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-15148139, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-16096354, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-16924957, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-17187377, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-17288500, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-17504181, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-17913691, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-18555983, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-2666846, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-3418520, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-7092921, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-8240390, http://linkedlifedata.com/resource/pubmed/commentcorrection/20156430-8622548
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1872-7786
pubmed:author
pubmed:copyrightInfo
Published by Elsevier Ireland Ltd.
pubmed:issnType
Electronic
pubmed:day
6
pubmed:volume
187
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-8
pubmed:dateRevised
2011-9-13
pubmed:meshHeading
pubmed-meshheading:20156430-Acetylcholinesterase, pubmed-meshheading:20156430-Animals, pubmed-meshheading:20156430-Apoptosis, pubmed-meshheading:20156430-Brain, pubmed-meshheading:20156430-Central Nervous System, pubmed-meshheading:20156430-Cholinesterase Reactivators, pubmed-meshheading:20156430-Dose-Response Relationship, Drug, pubmed-meshheading:20156430-Electroencephalography, pubmed-meshheading:20156430-Enzyme Activation, pubmed-meshheading:20156430-Guinea Pigs, pubmed-meshheading:20156430-Hippocampus, pubmed-meshheading:20156430-Isoflurophate, pubmed-meshheading:20156430-Male, pubmed-meshheading:20156430-Neurons, pubmed-meshheading:20156430-Peripheral Nervous System, pubmed-meshheading:20156430-Pralidoxime Compounds, pubmed-meshheading:20156430-Prodrugs, pubmed-meshheading:20156430-Skin, pubmed-meshheading:20156430-Soman, pubmed-meshheading:20156430-Status Epilepticus, pubmed-meshheading:20156430-Survival Analysis
pubmed:year
2010
pubmed:articleTitle
Pro-2-PAM therapy for central and peripheral cholinesterases.
pubmed:affiliation
Walter Reed Army Institute of Research, Division of Regulated Activities, Department of Regulated Laboratories, Silver Spring, MD 20910-7500, United States.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural